Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
• Age 18 or older
• Willing and able to provide informed consent
• Metastatic breast cancer, biopsy proven
‣ ER+/HER2-, defined as \>5% ER+ staining
⁃ HER2+ (regardless of ER status), including HER2-low and high expressors
• History of at least 6 months, sustained response to systemic therapy (clinically or radiographically defined as complete or stable response without progression)
• Isolated site of disease progression on FDG PET scan
• Consented to 12-245
• ECOG performance status 0-1